Further, the MAGL inhibitor JZL184 was shown to reduce osteolytic bone metastasis in mouse models of advanced breast and prostate cancer and osteosarcoma, and inhibited skeletal tumor growth, metastasis, and the formation of ectopic bone in models of osteosarcoma54. Here, MGLL is linked to prostate carcinoma.